Media headlines about Endo International (NASDAQ:ENDP) (TSE:ENL) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Endo International earned a daily sentiment score of 0.09 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.6461578455087 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news articles that may have impacted Accern’s analysis:
- Endo International (ENDP) Now Covered by B. Riley (americanbankingnews.com)
- OxyContin maker stops promoting opioids, cuts sales staff (finance.yahoo.com)
- Endo International plc – (ENDP) Short Interest Update (americanbankingnews.com)
- Trending Stocks in Review: Corcept Therapeutics Incorporated (NASDAQ:CORT), Endo International plc (NASDAQ … – The Oracle Examiner (oracleexaminer.com)
- Endo International (ENDP) to Commence Two Pivotal Phase 3 Clinical Trials Of Collagenase Clostridium Histolyticum … – StreetInsider.com (streetinsider.com)
ENDP has been the subject of several research analyst reports. Mizuho reiterated a “buy” rating and set a $12.00 target price (down previously from $14.00) on shares of Endo International in a research report on Wednesday, January 3rd. Leerink Swann started coverage on Endo International in a report on Tuesday, January 2nd. They set an “outperform” rating and a $12.00 price target for the company. Vetr upgraded Endo International from a “buy” rating to a “strong-buy” rating and set a $8.92 price target for the company in a report on Tuesday, December 26th. Zacks Investment Research cut Endo International from a “hold” rating to a “sell” rating in a report on Monday, January 15th. Finally, Cantor Fitzgerald set a $9.00 target price on Endo International and gave the stock a “hold” rating in a report on Monday, October 30th. Three investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Endo International presently has a consensus rating of “Hold” and an average price target of $10.51.
TRADEMARK VIOLATION NOTICE: This story was first reported by Week Herald and is the property of of Week Herald. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://weekherald.com/2018/02/15/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-endo-international-endp-share-price.html.
About Endo International
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.